Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
CB(Cannabinoid receptor) | 1 |
Target |
Mechanism CB agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date28 Dec 2021 |
Sponsor / Collaborator |
Start Date01 Aug 2021 |
Sponsor / Collaborator |
Start Date22 Jul 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cannabinol ( CB ) | Epidermolysis Bullosa, Junctional More | Phase 2 |
INM-089 | Age Related Macular Degeneration More | Preclinical |
INM-901 | Alzheimer Disease More | Preclinical |
NM-901 | Alzheimer Disease More | Discontinued |
INM-405 | Arthralgia More | Discontinued |